Incorporating financial toxicity considerations into clinical trial design to facilitate patient-centered decision-making in oncology

Laila A. Gharzai, Reshma Jagsi*

*Corresponding author for this work

Research output: Contribution to journalComment/debatepeer-review

3 Scopus citations

Abstract

Plain Language Summary: Financial toxicity is increasingly being recognized as an important and devastating consequence of cancer treatment that receives little attention when clinical trials are being designed. There is a significant need to obtain this important information in an era of increasingly expensive anticancer treatments. Patients who are informed of all implications of therapy—efficacy, side effects, cost, and broader financial impact—are able to select the best cancer treatment for themselves.

Original languageEnglish (US)
Pages (from-to)1143-1148
Number of pages6
Journalcancer
Volume129
Issue number8
DOIs
StatePublished - Apr 15 2023

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Incorporating financial toxicity considerations into clinical trial design to facilitate patient-centered decision-making in oncology'. Together they form a unique fingerprint.

Cite this